提高1H-MRS在区分胶质瘤复发与放射性坏死中的实用性
该回顾性研究基于81个活检匹配的波谱体素,建立以代谢物峰高比值为基础的1H-MRS标准,用于区分复发肿瘤(RT)与治疗后放射效应(PTRE)。五个比值达到可接受的敏感度与特异度平衡(AUC≥0.700),并各定义诊断RT的标准。在205例无活检匹配体素的记录中,应用这些标准与影像学诊断的一致性有待前瞻性研究验证。
要点
- 基于81个活检匹配波谱体素,五个代谢物比值AUC≥0.700,可用于区分RT与PTRE。
- Cho/Cr>1.54诊断RT的敏感度66%、特异度79%;Cr/Cho≤0.63敏感度65%、特异度79%。
- Lac/Lip≤1.64与Lip/Lac>0.58诊断RT的特异度均达95%。
核心结论
- 五个代谢物峰高比值达到可接受的敏感度与特异度平衡(AUC≥0.700),并各定义诊断RT的标准。
- 作者认为,前瞻性研究应用这些比值标准可能为活检或视觉波谱模式识别提供替代选择,以区分胶质瘤患者的RT与PTRE。
研究设计与样本
- 回顾性分析磁共振成像与1H-MRS数据。
- 使用81个活检匹配的波谱体素识别区分RT与PTRE的定量1H-MRS标准。
- 对205例无活检匹配体素的记录应用上述标准,检查其与影像学诊断的百分比一致性。
主要发现
- Cho/Cr>1.54诊断RT的敏感度66%、特异度79%。
- Cr/Cho≤0.63诊断RT的敏感度65%、特异度79%。
- Lac/Cho≤2.67诊断RT的敏感度85%、特异度58%。
- Lac/Lip≤1.64诊断RT的敏感度54%、特异度95%。
- Lip/Lac>0.58诊断RT的敏感度56%、特异度95%。
关键数值与推荐
- Cho/Cr>1.54诊断RT的敏感度66%、特异度79%。
- Cr/Cho≤0.63诊断RT的敏感度65%、特异度79%。
- Lac/Cho≤2.67诊断RT的敏感度85%、特异度58%。
- Lac/Lip≤1.64诊断RT的敏感度54%、特异度95%。
- Lip/Lac>0.58诊断RT的敏感度56%、特异度95%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Proton magnetic resonance spectroscopy (1H-MRS) has shown promise in distinguishing recurrent high-grade glioma from posttreatment radiation effect (PTRE). The purpose of this study was to establish objective 1H-MRS criteria based on metabolite peak height ratios to distinguish recurrent tumor (RT) from PTRE. A retrospective analysis of magnetic resonance imaging and 1H-MRS data was performed. Spectral metabolites analyzed included N-acetylaspartate, choline (Cho), creatine (Cr), lactate (Lac), and lipids (Lip). Quantitative 1H-MRS criteria to differentiate RT from PTRE were identified using 81 biopsy-matched spectral voxels. A receiver operating characteristic curve analysis was conducted for all metabolite ratio combinations with the pathology diagnosis as the classification variable. Forward discriminant analysis was used to identify ratio variables that maximized the correct classification of RT versus PTRE. Our results were applied to 205 records without biopsy-matched voxels to examine the percent agreement between our criteria and the radiologic diagnoses. Five ratios achieved an acceptable balance [area under the curve (AUC) ≥ 0.700] between sensitivity and specificity for distinguishing RT from PTRE, and each ratio defined a criterion for diagnosing RT. The ratios are as follows: Cho/Cr > 1.54 (sensitivity 66%, specificity 79%), Cr/Cho ≤ 0.63 (sensitivity 65%, specificity 79%), Lac/Cho ≤ 2.67 (sensitivity 85%, specificity 58%), Lac/Lip ≤ 1.64 (sensitivity 54%, specificity 95%), and Lip/Lac > 0.58 (sensitivity 56%, specificity 95%). Application of our ratio criteria in prospective studies may offer an alternative to biopsy or visual spectral pattern recognition to distinguish RT from PTRE in patients with gliomas.
引用
- Crain ID, Elias PS, Chapple K, et al. Improving the utility of 1H-MRS for the differentiation of glioma recurrence from radiation necrosis. J Neurooncol. 2017. PMID: 28555423. doi:10.1007/s11060-017-2407-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。